Drug safety alert for proton pump inhibitors
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update relating to proton pump inhibitors (PPIs). The update states that PPIs are associated very infrequently with cases of subacute cutaneous lupus erythematosus (SCLE), a non-scarring dermatosis that can develop in sun-exposed areas. More information is available from the MHRA website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069321
Recommended from Pharmaceutical Press